
    
      In selected patients who sign informed consent with decompensation of cardiac failure by
      water congestion will be allocated in two groups: Bumetanide and the other Indapamide group.
      Each group will be given the maximum tolerated dose for seven days with clinical evaluations
      every 48 hours. (Face to face and/or telephone). Clinical variables, ECG and serum and urine
      laboratories will be assessed finally, patients will follow up for 30 days. To identify
      endpoints such as: mortality, urinary failure, clinical deterioration, hospital admissions,
      edema. (MUCHO).
    
  